Purpose Current literature on clinical controversies surrounding the use of thrombolytic
agents in patients with intermediate-risk pulmonary embolism (PE) is reviewed. Summary …

Background The role of thrombolytic agents in the treatment of pulmonary thromboembolism
(PTE) remains a controversial issue. The objective of this study is to assess the efficacy and …

Acute pulmonary embolism represents a major complication of venous thromboembolism
that is associated with high morbidity and mortality. Guidelines recommend the rapid …

While systemic intravenous thrombolysis decreases mortality in patients with high-risk
pulmonary embolism (PE), it clearly increases haemorrhagic risk. There are many …

Background: Systemic thrombolysis (ST) is the guideline-recommended treatment for high-
risk pulmonary embolism (PE), although catheter-directed thrombolysis (CDT) may provide a …

Background The use of thrombolysis in patients with acute, intermediate-risk pulmonary
embolism (PE) remains controversial. This meta-analysis compared the efficacy and safety …

More than thirty years have passed since streptokinase was first shown to dissolve
pulmonary arterial thrombi and normalize pulmonary artery pressure in patients with acute …

Background The use of thrombolytic therapy in patients with intermediate-risk pulmonary
embolism is controversial. To compare with anticoagulation alone, no analysis before has …

Opinion statement Treatment of pulmonary embolism (PE) is variable amongst different and
even the same institutions. With the introduction of different forms of thrombolysis, catheter …

Background Benefit of thrombolytic therapy in patients with massive pulmonary embolism
(PE) is evident. However, evidence supporting benefit in clinical outcomes of this approach …